The outcomes of these investigations have demonstrated significant cytotoxic effects on cancer cell populations in GBM, renal cell carcinoma (RCC), and head and neck squamous cell carcinoma (HNSCC), highlighting the potential of this targeted approach in the treatment of cancers expressing IL-13Rα2 [108]. The gene discussed is IL13RA2; the disease is glioblastoma.